Interestingly, PPT1 inhibition by HCQ or DC661 also led to an increased effect of anti-PD-1 therapy in melanoma in vitro and in a murine in vivo model [133], echoing findings recently made in pancreatic cancer [50]. This evidence concerns the gene PPT1 and melanoma.